Method for treating neurodegenerative disorders

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007200

Reexamination Certificate

active

07018797

ABSTRACT:
The invention is directed to a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.

REFERENCES:
patent: 4988700 (1991-01-01), Traber et al.
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 6689570 (2004-02-01), Andrew et al.
patent: 6689574 (2004-02-01), Cummings et al.
patent: 6689578 (2004-02-01), DeZwaan et al.
patent: 637 363 (1983-07-01), None
patent: 360 077 (1990-03-01), None
Auld et al., Beta Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci, (1998) 21, 43-49.
Arneric et al., Structure- Activity Relationships of 2-Aminotetralins and 2-Aminoindanes: Inhibitory Neuroeffector Mechanisms in Isolated Guinea-Pig IIea, Arch Int Pharmacodyn, (1982) 258, 84-99.
Seiler and Markstein, Further Characterization of Structural Requirements for Agonists at the Striatal Dopamine D2 Receptor and a Comparison with Those at the Striatal Dopamine D1 Receptor, Molecular Pharmacology, (1984) 26, 452-457.
Atwal et al., Substituted 1,2,3,4- Tetrahydroaminonaphthols: Antihypertensive Agents, Calcium Channel Blockers, and Adrenergic Receptor Blockers with Catecholamine-Depleting Effects, J Med Chem, (1987) vol. 30, No. 4, 627-635.
Mellin et al., Central Dopaminergic and 5-Hydroxytryptaminergic Effects of C3-Methylated Derivatives of 8-Hydroxy-2-(di-n-propylamino)tetralin, J Med Chem, (1988) vol. 31, No. 6, 1130-1140.
Kihara et al., “Nicotine receptor stimulation protects neurons against beta-amyloid toxicity”, Annals of Neurology, Aug. 1997, vol. 42, No. 2, 159-163.
Kihara et al., Neuroprotective effect of nicotine-related substances against beta-amyloid cytotoxicity, Neurosci. Res., 1997, p. S158, abstract 1230.
Itoh et al., “Dysfunction of Cholinergic and dopaminergic neuronal systems in beta-amyloid protein-infused rats” J. Neurochem, vol. 66, No. 3, 1996, pp. 1113-1117.
Salomon et al., “Nicotine inhibits amyloid formation by the beta-peptide”, BIOCHEMISTRY, vol. 35 No. 42, 1996, pp. 13568-13578.
Maurice et al., “Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction” Brain Res., vol. 706, No. 2, 1996 pp. 181-193.
Zamani et al., “Nicotine modulates the neurotoxic effect of beta-amyloid protein (25-35) in hippocampal cultures” NEUROREPORT vol. 8, No. 2, Jan. 1997, pp. 513-517.
Sjoberg et al., “Neuronal nicotine receptor activation: a promising strategy for the treatment of Alzheimer's disease?” Int. J. Geriatric Psychopharmacology, vol. 1, No. 3, 1998, pp. 145-149.
McDermed et al., “Synthesis and pharmacology of some 2-aminotetralins Dopamine receptor Agonists”, J. Med. Chem., vol. 18, No. 4, 1975, pp. 362-367.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for treating neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treating neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating neurodegenerative disorders will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3605031

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.